# OutSense

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/outsense

- Industry: Medical Devices & Equipment
- Headquarters: Or Yehuda, Israel
- Website: www.outsense.co.il
- Total disclosed funding: $2.8M
- Latest round: Series A (Jun 7, 2021)
- Investors on record: 2

## About

Based in Israel, OutSense develops innovative IoT technology for remote analysis and diagnosis of human waste, enhancing health monitoring and early detection of medical conditions through advanced sensors and AI-driven analytics.OutSense, founded in 2016 in Or Yehuda, Israel, specializes in IoT solutions for healthcare diagnostics. The company has secured a total of 4 deals, with its most recent funding round occurring on June 7, 2021. The latest round of funding was a Series A, raising USD 500,000, led by Longevity Venture Partners, bringing the total amount raised to USD 500,000. Yfat Scialom serves as the CEO.OutSense Diagnostics specializes in groundbreaking IoT technology that provides remote analysis and diagnosis of human waste from within a standard toilet bowl. The core product consists of a patented device that clips onto the toilet and utilizes an advanced smart optical sensor to autonomously scan urine and stool. This data is then transmitted to a secure cloud platform, where it undergoes analysis through sophisticated imaging algorithms and artificial intelligence tools, allowing for real-time health monitoring and early detection of medical conditions. The company primarily targets healthcare providers and institutions, offering a monitoring solution that can seamlessly integrate into existing Health Information Systems (HIS) and be accessed via a dedicated mobile application. Currently, its products are marketed to healthcare organizations and clinical settings in regions including North America and Europe, where there is a growing demand for innovative health diagnostic solutions.OutSense Diagnostics generates revenue through a subscription-based model, where healthcare facilities pay for continuous access to their diagnostic platform and associated services. Clients typically include hospitals, long-term care facilities, and health organizations that seek to enhance patient monitoring capabilities without requiring user intervention. The structured transaction framework allows clients to receive ongoing data analysis and alerts regarding potential health deviations, fostering timely medical responses. Specific pricing plans are tailored to the needs of individual facilities, factoring in the scale of implementation and the volume of data processed. The flagship service revolves around the real-time analysis of human waste, which is critical for conditions such as colorectal cancer and urinary tract infections, making it an essential offering for organizations focused on preventative healthcare and patient safety.In June 2021, OutSense raised USD 500,000 in Series A funding led by Longevity Venture Partners, as part of a larger USD 2.7 million Series A funding initiative. The company plans to utilize this funding to support product development and preparations for large-scale production. OutSense aims to launch upcoming products that will enhance its diagnostic capabilities and expand its reach into additional markets, particularly in North America and Europe, by the end of 2023.

## Funding rounds

- Series A, Jun 7, 2021, $0.5M — Longevity Venture Partners
- Series A, Nov 9, 2020, $2.2M — Peregrine Ventures
- Seed, Aug 1, 2016, $0.1M — Peregrine Ventures

## Investors

- Peregrine Ventures (https://capitalatlas.ai/funds/peregrine-ventures) — Seed, Series A
- Longevity Venture Partners (https://capitalatlas.ai/funds/longevity-venture-partners) — Series A